DARINAPARSIN:
PMDA approved
Darinaparsin is a novel organic arsenical under evaluation as a cancer chemotherapeutic and has a similar structure to one of the intermediates of the arsenic detoxification pathway, and is expected to have lower toxicity than inorganic arsenic.
MECHANISM OF ACTION:
- Disruption of mitochondrial functions
- Increase in reactive oxygen species (ROS) production
- Induction of apoptosis
- Arrest of the cell cycle at the G2/M phase
- Potent anti-angiogenesis activity
INDICATIONS:
Relapse / Refractory PTCL:
- PTCL, not otherwise specified (PTCL-NOS)
- Angioimmunoblastic T-cell Lymphoma (AITL)
- Anaplastic Large Cell Lymphoma (ALCL) ALK-positive/negative
For any medical enquiry, Contact us at +91 9591736262 or Email us at info@sayretherapeutics.com
